美国 · 平台与数据 · TipRanks
GenFleet Advances GFH276 Combination Study in RAS-Mutant Cancers
详细摘要
Inc. Class H ( ($HK:2595) ) has issued an announcement. GenFleet Therapeutics (Shanghai) Inc. is advancing GFH276, an oral Pan ...
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.tipranks.com)




